Sakhanda Wire
NVDA $154.00 -1.37% MSFT $506.28 -2.26% GOOGL $280.87 -1.00% META $620.34 -0.97% AMZN $256.88 -0.34%
← Back to the news

Basecamp Research raises $140 million for AI-built biological therapies

London-based Basecamp Research has raised $140 million in a funding round led by S32, with participation from Nvidia, Anthropic’s Anthology Fund, the NATO Innovation Fund and Redalpine. Founded in 2020, the company plans to expand its biological AI models, called EDEN, and advance drug and cell-therapy candidates toward clinical development.

EDEN models are trained on DNA collected from environmental samples, including rainforest soil, volcanic sites and the deep sea. Basecamp says its research network covers more than 30 countries and all seven continents. The company’s dataset contained about 15 trillion DNA building blocks at the time of an interview, while an earlier EDEN model used 9.7 trillion blocks from more than a million newly sequenced species.

The company is designing antibiotics and enzymes intended to insert genes at precise locations in human cells. Basecamp says an antibiotic candidate, EDEN-7, performed in mice with multidrug-resistant bacteria about as well as a last-resort antibiotic. It also reported activity from gene-insertion enzymes and tumor-cell clearance by modified human T cells in laboratory tests. These findings remain preclinical: human trials must establish whether the therapies are safe and effective, while delivery and possible toxicity remain challenges.

Written by Sakhanda Wire AI from reporting by The Decoder. Facts, quotes and full context are in the original article below.

Originally published by The Decoder on

Read the original on The Decoder ↗

The reporting and the image belong to The Decoder and are credited and linked above; the text on this page is Sakhanda Wire's own summary.

← Back to the news

More stories

All the latest news